Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences (GILD) offers a forward dividend yield of approximately 2.24% with an annual dividend of $3.28 per share.
• The company pays dividends quarterly at $0.82 per share following a 3.8% increase announced for 2026.
• GILD has raised its dividend for 10 consecutive years, reflecting consistent growth.
• Payout ratios remain moderate at around 43% of earnings, supported by cash flow coverage.
• The yield sits below the broader pharmaceutical industry average of 2.8%, indicating a conservative profile.
• Strong free cash flow and financial stability suggest the dividend is sustainable for income-focused investors.

Dividend Overview

Gilead Sciences (GILD) maintains a quarterly dividend policy with payments of $0.82 per share. This results in an annualized dividend of $3.28 and a forward yield near 2.24%. The most recent ex-dividend date is September 15, 2026, with payment scheduled for September 29, 2026. The company qualifies as a modest-yield dividend stock rather than a high-yield play, appealing primarily to investors seeking steady income combined with potential capital appreciation in the biotechnology sector.

Dividend History and Growth

GILD has demonstrated reliable dividend growth, increasing its payout for 10 consecutive years. The most recent adjustment was a 3.8% hike to $0.82 per share in early 2026. Historical data shows average annual dividend growth rates between 3% and 6% over multiple periods, underscoring a long-term strategy of gradual increases supported by the company’s cash generation from its HIV and antiviral portfolio. No dividend cuts have occurred in the recent past.

Dividend Sustainability and Payout Ratio

The dividend appears sustainable, with an earnings payout ratio around 43% and cash flow coverage in the 31% to 43% range. These levels provide a comfortable margin, even amid periodic earnings variability common in biotechnology. Gilead Sciences maintains a solid balance sheet with manageable debt, and free cash flow remains sufficient to cover distributions. Future increases will continue to depend on board approval and ongoing operational performance.

Dividend Compared to Industry Peers

Within the pharmaceutical and biotechnology sector, GILD’s yield of approximately 2.24% falls below the industry average of 2.8%. Peers often offer higher yields but may carry greater payout ratios or less consistent growth records. Gilead’s profile stands out for its conservative approach, prioritizing dividend stability and growth over aggressive yield maximization.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening.

Is This Stock Attractive for Dividend Investors?

GILD may suit long-term dividend growth investors who value consistency over high current yields. Its 10-year streak of increases and moderate payout ratios provide a foundation for potential future growth, while the conservative yield appeals to those seeking balance between income and reinvestment opportunities. Conservative investors focused on financial stability in healthcare may find the stock’s cash-flow coverage attractive, though those prioritizing higher immediate income might look elsewhere in the sector. The company’s position in established therapeutic areas supports ongoing dividend capacity without excessive risk to distributions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations